Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 4;13(9):840.
doi: 10.3390/antibiotics13090840.

Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest

Affiliations

Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest

Mohammad Asadzadeh et al. Antibiotics (Basel). .

Abstract

Multidrug-resistant Candida auris has recently caused major outbreaks in healthcare facilities. Rapid and accurate antifungal susceptibility testing (AST) of C. auris is crucial for proper management of invasive infections. The Commercial Sensititre Yeast One and Vitek 2 methods underestimate or overestimate the resistance of C. auris to fluconazole and amphotericin B (AMB). This study evaluated the AST results of C. auris against fluconazole and AMB by gradient-MIC-strip (Etest) and broth microdilution-based MICRONAUT-AM-EUCAST (MCN-AM) assays. Clinical C. auris isolates (n = 121) identified by phenotypic and molecular methods were tested. Essential agreement (EA, ±1 two-fold dilution) between the two methods and categorical agreement (CA) based on the Centers for Disease Control and Prevention's (CDC's) tentative resistance breakpoints were determined. Fluconazole resistance-associated mutations were detected by PCR-sequencing of ERG11. All isolates identified as C. auris belonged to South Asian clade I and contained the ERG11 Y132F or K143R mutation. The Etest-MCN-AM EA was poor (33%) for fluconazole and moderate (76%) for AMB. The CA for fluconazole was higher (94.2%, 7 discrepancies) than for AMB (91.7%, 10 discrepancies). Discrepancies were reduced when an MCN-AM upper-limit value of 4 µg/mL for fluconazole-susceptible C. auris and an Etest upper-limit value of 8 µg/mL for the wild type for AMB were used. Our data show that resistance to fluconazole was underestimated by MCN-AM, while resistance to AMB was overestimated by Etest when using the CDC's tentative resistance breakpoints of ≥32 µg/mL for fluconazole and ≥2 µg/mL for AMB. Method-specific resistance breakpoints should be devised for accurate AST of clinical C. auris isolates for proper patient management.

Keywords: Candida auris; Etest; MICRONAUT-AM EUCAST assay; antifungal susceptibility testing; comparative performance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Similar articles

Cited by

References

    1. Meis J.F., Chowdhary A. Candida auris: A global fungal public health threat. Lancet Infect. Dis. 2018;18:1298–1299. doi: 10.1016/S1473-3099(18)30609-1. - DOI - PubMed
    1. Ahmad S., Alfouzan W. Candida auris: Epidemiology, diagnosis, pathogenesis, antifungal susceptibility and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms. 2021;9:807. doi: 10.3390/microorganisms9040807. - DOI - PMC - PubMed
    1. Kohlenberg A., Monnet D.L., Plachouras D., Candida auris Survey Collaborative Group Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Euro. Surveill. 2022;27:2200846. doi: 10.2807/1560-7917.ES.2022.27.46.2200846. - DOI - PMC - PubMed
    1. Thatchanamoorthy N., Rukumani Devi V., Chandramathi S., Tay S.T. Candida auris: A mini review on epidemiology in healthcare facilities in Asia. J. Fungi. 2022;8:1126. doi: 10.3390/jof8111126. - DOI - PMC - PubMed
    1. Dbeibo L., Beeler C., Clark L., Zondor M., Sartino C., Relich R.F., Hazen D., Lyons K., Kelley K., Webb D., et al. Candida auris outbreak at a tertiary care hospital during the COVID-19 pandemic. Am. J. Infect. Control. 2024;52:878–883. doi: 10.1016/j.ajic.2024.03.012. - DOI - PubMed

LinkOut - more resources